Treatment of Infections by OXA-48-Producing Enterobacteriaceae

Adam G. Stewart(Royal Brisbane and Women's Hospital), David L. Paterson(The University of Queensland), Patrick N. A. Harris(The University of Queensland), Andrew Henderson(The University of Queensland)

Antimicrobial Agents and Chemotherapy

August 13, 2018

10.1128/aac.01195-18

Cited by 146

Related Papers

Antimicrobial Resistance in ESKAPE Pathogens

|Clinical Microbiology Reviews|2020|2k

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance

|JAMA|2018|761

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

|The Lancet Infectious Diseases|2017|521

The emerging threat of multidrug-resistant Gram-negative bacteria in urology

|Nature Reviews Urology|2015|367

Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study

|The Lancet Infectious Diseases|2021|338